Download
fimmu-11-00970.pdf 867,67KB
WeightNameValue
1000 Titel
  • Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
1000 Autor/in
  1. Covián, Camila |
  2. Retamal-Díaz, Angello |
  3. Bueno, Susan M. |
  4. Kalergis, Alexis M. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-05-08
1000 Erschienen in
1000 Quellenangabe
  • 11:970
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2020.00970 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227382/ |
1000 Ergänzendes Material
  • https://www.frontiersin.org/articles/10.3389/fimmu.2020.00970/full#h9 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Trained immunity is a type of non-specific memory-like immune response induced by some pathogens and vaccines, such as BCG, which can confer antigen-independent protection against a wide variety of pathogens. The BCG vaccine has been extensively used to protect against tuberculosis for almost a 100 years. Interestingly, this vaccine reduces children's mortality caused by infections unrelated to Mycobacterium tuberculosis infection, a phenomenon thought to be due to the induction of trained immunity. The SARS-CoV-2 pandemic has infected, as of April 22, 2020, 2,623,231 people globally, causing a major public health problem worldwide. Currently, no vaccine or treatment is available to control this pandemic. We analyzed the number of positive cases and deaths in different countries and correlated them with the inclusion of BCG vaccination at birth in their national vaccination programs. Interestingly, those countries where BCG vaccination is given at birth have shown a lower contagion rate and fewer COVID-19-related deaths, suggesting that this vaccine may induce trained immunity that could confer some protection for SARS-CoV-2.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal BCG
lokal trained immunity
lokal SARS-CoV-2
lokal innate immunity
lokal vaccine
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q292acOhbiwgQ2FtaWxh|https://frl.publisso.de/adhoc/uri/UmV0YW1hbC1Ew61heiwgQW5nZWxsbw==|https://frl.publisso.de/adhoc/uri/QnVlbm8sIFN1c2FuIE0u|https://frl.publisso.de/adhoc/uri/S2FsZXJnaXMsIEFsZXhpcyBNLg==
1000 Label
1000 Förderer
  1. Comisión Nacional de Investigación Científica y Tecnológica |
  2. Instituto Milenio en Inmunología e Inmunoterapia |
  3. Regional Government of Antofagasta |
  4. Fondo Nacional de Desarrollo Científico y Tecnológico |
1000 Fördernummer
  1. I781902009
  2. P09/016-F
  3. 30488811-0
  4. 1190830
1000 Förderprogramm
  1. -
  2. -
  3. Innovation Fund for Competitiveness FIC-R 2017
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Comisión Nacional de Investigación Científica y Tecnológica |
    1000 Förderprogramm -
    1000 Fördernummer I781902009
  2. 1000 joinedFunding-child
    1000 Förderer Instituto Milenio en Inmunología e Inmunoterapia |
    1000 Förderprogramm -
    1000 Fördernummer P09/016-F
  3. 1000 joinedFunding-child
    1000 Förderer Regional Government of Antofagasta |
    1000 Förderprogramm Innovation Fund for Competitiveness FIC-R 2017
    1000 Fördernummer 30488811-0
  4. 1000 joinedFunding-child
    1000 Förderer Fondo Nacional de Desarrollo Científico y Tecnológico |
    1000 Förderprogramm -
    1000 Fördernummer 1190830
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6428056.rdf
1000 Erstellt am 2021-06-08T18:12:47.961+0200
1000 Erstellt von 218
1000 beschreibt frl:6428056
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2021-06-24T11:16:05.823+0200
1000 Objekt bearb. Thu Jun 24 11:15:50 CEST 2021
1000 Vgl. frl:6428056
1000 Oai Id
  1. oai:frl.publisso.de:frl:6428056 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source